FDA grants rare pediatric disease designation to Summit Therapeutics’ DMD drug
Summit Therapeutics has received second drug designation from the US Food and Drug Adminstration for ezutromid, a treatment for Duchenne Muscular Dystrophy (DMD).
Click on this link for more information.
